CD200 Expression on Apoptotic DCs and Immune Tolerance
CD200 Expression on Apoptotic DCs and Immune Tolerance
批准号:
6918010
负责人:
Robert L Truitt
金额:
$22.73万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-08-01 至 2007-07-31
关键词:
T lymphocyteapoptosisautoantigenscellular immunitycysteine endopeptidasesdendritic cellsgene expressiongene interactiongenetically modified animalsgrowth factorhaptenshistoneshuman subjectimmune responseimmune tolerance /unresponsivenessimmunogeneticskeratinocytelaboratory mousemessenger RNAmyelin basic proteinsmyelocyteplasma cellspolymerase chain reactiontissue /cell culture
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): During apoptotic cell death, biochemical processes, including the action of caspases, modify self-proteins and create potential autoantigens. To maintain a steady-state in the face of natural cell turnover, the immune system must have a mechanism to prevent or control responses to cell death-associated autoantigens or risk autoimmunity. CD200 is a transmembrane glycoprotein that shares sequence homology with the B7-family of T cell costimulatory molecules and is known to impart a T cell tolerogenic signal. We made the novel observation that CD200 mRNA and protein expression was increased in apoptotic murine dendritic cells (DCs). We identified functional p53-response elements within the CD200 gene. We identified both p53- and caspase-dependent pathways leading to increased expression of CD200 on apoptotic DCs. CD200 on apoptotic DCs significantly altered the rate of T cell proliferation and the cytokine profile in autologous MLR cultures. Furthermore, using CD200 knockout mice, we found that CD200 was essential for induction of UVB-mediated immune tolerance to haptenated proteins in contact hypersensitivity assays. Based on our mouse data, we hypothesize that CD200 expression on apoptotic DCs contributes to the induction of immune tolerance to caspase-generated self-peptides in vivo. We propose to test this hypothesis in vivo using an established mouse model of immune tolerance to hapten and to extend our studies to human DCs and immune responses to both caspase-generated self-peptides and model autoantigens in vitro. Our Specific Aims are: (1) To determine whether CD200 on infused or resident DCs plays a role in the induction of immune tolerance to hapten using wild-type and CD200 knockout mice; (2) To assess the expression of CD200 mRNA and protein in subsets of human DCs and in cultures of primary keratinocytes with and without induction of apoptosis; and (3) To test the effect of blocking CD200/CD200R interaction on T cell responses to caspase-generated self-peptides, nucleohistone and myelin basic protein using PBMC from normal individuals and multiple sclerosis patients. If the data support our hypothesis, we will have identified CD200 expression on apoptotic DCs as an important molecule in maintaining self-tolerance in humans and, perhaps, in limiting autoimmunity. These studies will also provide new insight into a novel molecular pathway that is a target for enhancement of antitumor immunity and for prevention of graft rejection.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1111/j.0022-202x.2004.23461.x
发表时间:
2004-11-01
期刊:
JOURNAL OF INVESTIGATIVE DERMATOLOGY
影响因子:
6.5
作者:
[Rosenblum, MD, Olasz, EB, Truitt, RL]
通讯作者:
Truitt, RL
Characterization of CD 200-receptor expression in the murine epidermis.
小鼠表皮中 CD 200 受体表达的表征。
DOI:
10.1111/j.0022-202x.2005.23948.x
发表时间:
2005
期刊:
The Journal of investigative dermatology.
影响因子:
--
作者:
[Rosenblum,MichaelD, Woodliff,JeffreyE, Madsen,NathanielA, McOlash,LauraJ, Keller,MelissaR, Truitt,RobertL]
通讯作者:
Truitt,RobertL
CD200, a "no danger" signal for hair follicles.
CD200,毛囊的“无危险”信号。
DOI:
10.1016/j.jdermsci.2005.11.003
发表时间:
2006
期刊:
Journal of dermatological science
影响因子:
4.6
作者:
[Rosenblum,MichaelD, Yancey,KimB, Olasz,EditB, Truitt,RobertL]
通讯作者:
Truitt,RobertL
CD200 Expression on Apoptotic DCs and Immune Tolerance
-
批准号:6779014
-
项目类别:
-
资助金额:$22.73万
-
财政年份:2004
-
负责人:Robert L Truitt
-
依托单位:
Allospecific Immunoregulatory T Cells in BMT Recipients
-
批准号:6528199
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2001
-
负责人:Robert L Truitt
-
依托单位:
Allospecific Immunoregulatory T Cells in BMT Recipients
-
批准号:6644796
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2001
-
负责人:Robert L Truitt
-
依托单位:
Allospecific Immunoregulatory T Cells in BMT Recipients
-
批准号:6353234
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2001
-
负责人:Robert L Truitt
-
依托单位:
FACS VANTAGE/SE
-
批准号:6052086
-
项目类别:
-
资助金额:$22.68万
-
财政年份:2000
-
负责人:Robert L Truitt
-
依托单位:
RLTB--A NOVEL IMMUNOMODULATORY AGENT FOR USE IN BMT
-
批准号:2654270
-
项目类别:
-
资助金额:$20.87万
-
财政年份:1997
-
负责人:Robert L Truitt
-
依托单位:
RLTB--A NOVEL IMMUNOMODULATORY AGENT FOR USE IN BMT
-
批准号:2011743
-
项目类别:
-
资助金额:$20.26万
-
财政年份:1997
-
负责人:Robert L Truitt
-
依托单位:
RLTB--A NOVEL IMMUNOMODULATORY AGENT FOR USE IN BMT
-
批准号:2871942
-
项目类别:
-
资助金额:$21.5万
-
财政年份:1997
-
负责人:Robert L Truitt
-
依托单位:
MANIPULATION OF GVL/GVH REACTIONS IN ALLOGENEIC BMT
-
批准号:2089996
-
项目类别:
-
资助金额:$2.53万
-
财政年份:1984
-
负责人:Robert L Truitt
-
依托单位:
CLONAL CVL/GVH REACTIONS AND ADOPTIVE IMMUNOTHERAPY
-
批准号:3179232
-
项目类别:
-
资助金额:$18.76万
-
财政年份:1984
-
负责人:Robert L Truitt
-
依托单位:
MECHANISMS IN SUCCESSFUL THERAPY OF GVHD WITH MOAB
-
批准号:2871697
-
项目类别:
-
资助金额:$19.89万
-
财政年份:1984
-
负责人:Robert L Truitt
-
依托单位:
MECHANISMS IN SUCCESSFUL THERAPY OF GVHD WITH MOAB
-
批准号:2007505
-
项目类别:
-
资助金额:$18.83万
-
财政年份:1984
-
负责人:Robert L Truitt
-
依托单位:
MANIPULATION OF GVL/GVH REACTIONS IN ALLOGENEIC BMT
-
批准号:2089995
-
项目类别:
-
资助金额:$19.0万
-
财政年份:1984
-
负责人:Robert L Truitt
-
依托单位:
CLONAL CVL/GVH REACTIONS AND ADOPTIVE IMMUNOTHERAPY
-
批准号:3179231
-
项目类别:
-
资助金额:$18.07万
-
财政年份:1984
-
负责人:Robert L Truitt
-
依托单位:
MECHANISMS IN SUCCESSFUL THERAPY OF GVHD WITH MOAB
-
批准号:2654002
-
项目类别:
-
资助金额:$19.31万
-
财政年份:1984
-
负责人:Robert L Truitt
-
依托单位:
CLONAL GVL/GVH REACTIONS AND ADOPTIVE IMMUNOTHERAPY
-
批准号:3179233
-
项目类别:
-
资助金额:$18.89万
-
财政年份:1984
-
负责人:Robert L Truitt
-
依托单位:
CLONAL CVL/GVH REACTIONS AND ADOPTIVE IMMUNOTHERAPY
-
批准号:3179226
-
项目类别:
-
资助金额:$15.76万
-
财政年份:1984
-
负责人:Robert L Truitt
-
依托单位:
IMMUNOREGULATORY T CELLS IN TRANSPLATATION TOLERANCE
-
批准号:3133300
-
项目类别:
-
资助金额:$18.02万
-
财政年份:1984
-
负责人:Robert L Truitt
-
依托单位:
MECHANISMS IN SUCCESSFUL THERAPY OF GVHD WITH MOAB
-
批准号:6150023
-
项目类别:
-
资助金额:$20.48万
-
财政年份:1984
-
负责人:Robert L Truitt
-
依托单位:
MANIPULATION OF GVL/GVH REACTIONS IN ALLOGENEIC BMT
-
批准号:3179228
-
项目类别:
-
资助金额:$18.36万
-
财政年份:1984
-
负责人:Robert L Truitt
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
-
批准号:31970691
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:张胜萍
-
依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
-
批准号:31900527
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:孙磊
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
姜黄素与TRAIL的协同抗肿瘤机制研究
-
批准号:31101223
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2011
-
负责人:曹林
-
依托单位:
转凝蛋白通过线粒体凋亡途径致足细胞凋亡的机制研究
-
批准号:81100502
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:管娜
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位: